Findings

What do systematic reviews say?

29 questions · 30 findings · 11 reviews · Metabolic and Endocrine Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 11 · 36.7%GRADE not reported 0 · 0%Very low 13 · 43.3%Low 3 · 10%Moderate 3 · 10%High 0 · 0%

Testosterone vs placebo

Cardiovascular mortality · men with sexual dysfunction

The review found no eligible studies for this question.

2 findings from 1 review

Testosterone replacement in men with sexual dysfunction 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Testosterone replacement in men with sexual dysfunction 2024 · Cochrane Headline outcomes only
RR 0.83 [0.21, 3.26]
10 studies · 3525 participants
Moderate

Testosterone vs PDE5I

Cardiovascular mortality · men with sexual dysfunction

The review found no eligible studies for this question.

1 finding from 1 review

Testosterone replacement in men with sexual dysfunction 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Testosterone as an add‐on to PDE5I vs PDE5I

Cardiovascular mortality · men with sexual dysfunction

The review found no eligible studies for this question.

1 finding from 1 review

Testosterone replacement in men with sexual dysfunction 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs meglitinides

Cardiovascular mortality

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs insulin

Cardiovascular mortality

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Cardiovascular mortality · people at increased risk for developing type 2 diabetes

The review found no eligible studies for this question.

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: pioglitazone monotherapy vs intensive behaviour‐changing intervention

Cardiovascular mortality · people at increased risk for developing type 2 diabetes

The review found no eligible studies for this question.

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: pioglitazone monotherapy vs no intervention

Cardiovascular mortality · people at increased risk for developing type 2 diabetes

The review found no eligible studies for this question.

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs diet and exercise or another antidiabetic drug

Cardiovascular mortality · people at increased risk for developing type 2 diabetes

The review found no eligible studies for this question.

1 finding from 1 review

Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table for metformin plus intensive diet and exercise vs intensive diet and exercise

Cardiovascular mortality · people at increased risk for developing type 2 diabetes

The review found no eligible studies for this question.

1 finding from 1 review

Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Acarbose vs no intervention

Cardiovascular mortality · people at increased risk for developing type 2 diabetes

It is very uncertain whether acarbose changes cardiovascular mortality compared with no intervention (very low certainty).

1 finding from 1 review

Alpha‐glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in… 2018 · Cochrane Headline outcomes only
RR 0.64 [0.16, 2.56]
2 studies · 205 participants
Very low

Acarbose vs placebo

Cardiovascular mortality · people at increased risk for developing type 2 diabetes

It is very uncertain whether acarbose changes cardiovascular mortality compared with placebo (very low certainty).

1 finding from 1 review

Alpha‐glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in… 2018 · Cochrane Headline outcomes only
RR 0.88 [0.71, 1.1]
3 studies · 8069 participants
Very low

Diet vs physical activity or standard treatment

Cardiovascular mortality · people at increased risk for developing type 2 diabetes

1 finding from 1 review

Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 530 participants
Very low

Physical activity vs usual care

Cardiovascular mortality · people at increased risk for developing type 2 diabetes

1 finding from 1 review

Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 274 participants
Very low

Adverse event outcomes for dietary combined with physical activity interventions vs usual care

Cardiovascular mortality · people at increased risk for developing type 2 diabetes

It is very uncertain whether diet plus physical activity changes cardiovascular mortality compared with standard treatment (very low certainty).

1 finding from 1 review

Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications… 2017 · Cochrane Headline outcomes only
RR 0.94 [0.24, 3.65]
7 studies · 3263 participants
Very low

Intervention not reported

Cardiovascular mortality · people at risk for development of T2DM

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 2281 participants
Very low

Intervention not reported

Cardiovascular mortality · people at risk for development of T2DM

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 179 participants
Very low

Intervention not reported

Cardiovascular mortality · people at risk for the development of type 2 diabetes mellitus

1 finding from 1 review

Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons… 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 9306 participants
Moderate

Intervention not reported

Cardiovascular mortality · people at risk for the development of type 2 diabetes mellitus

1 finding from 1 review

Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons… 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 274 participants
Very low

Intensive glycaemic control vs conventional glucose control

Cardiovascular mortality · patients with type 2 diabetes mellitus

Intensive glycaemic control showed no clear difference in cardiovascular mortality compared with conventional glycaemic control (moderate certainty).

1 finding from 1 review

Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus 2013 · Cochrane Headline outcomes only
RR 1.06 [0.94, 1.21]
22 studies · 34177 participants
Moderate